# Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

> **NCT02368951** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 20 (actual)

## Conditions studied

- Medical Oncology

## Interventions

- **DRUG:** BAY1187982

## Key facts

- **NCT ID:** NCT02368951
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-24
- **Primary completion:** 2016-07-27
- **Final completion:** 2016-07-27
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02368951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02368951, "Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02368951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*